Substituted prolines/piperidines as orexin receptor antagonists
The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as OX 1 or OX 2 , or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention. For example, orexin receptor-modulatory compounds of the present invention can be used in treatment of an eating disorder, obesity, alcoholism or an alcohol-related disorder, drug abuse or addiction including addiction to cocaine, opiates, amphetamines, or nicotine, a sleep disorder, a cognitive dysfunction in a psychiatric or neurologic disorder, depression, anxiety, panic disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, headache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases, cancer, hypertension, behavior disorder, mood disorder, manic depression, dementia, sex disorder, psychosexual disorder, or renal disease.
1. A compound of formula (I),
wherein
A is aryl or heteroaryl;
B is absent, or B is aryl, aryloxy, heteroaryl, or heteroaryloxy;
wherein A or B can each independently be unsubstituted or can each independently be mono- or multi-substituted with J or R′, or both;
D is aryl, aroyl, heteroaryl, or heteroaroyl, wherein D can be unsubstituted or can be mono- or independently multi-substituted with J or R′, or both;
Z is N or O, provided that when Z is O, R 2 is absent;
R 1 , independently at each occurrence, is selected from the group consisting of halo, oxo, hydroxy, cyano, (C 1-4 )alkyl, (C 1-4 )alkoxy, (C 1-4 )acyloxy, (C 1-4 )acylamido, haloalkyl, haloalkoxy, NR a R b , C(═O)NR a R b , C(═O)OR a , SO 2 R a , SO 2 NR a R b , cycloalkyl, heterocyclyl, aryl, aralkyl, and heteroaryl;
R a and R b , independently at each occurrence, are each selected from the group consisting of H, (C 1-4 )alkyl, aralkyl, (C 1-5 )acyl, or R a and R b together with the nitrogen atom to which they are bonded form a 4-7 membered ring optionally further comprising 1 or 2 NR c , O, S, SO, or SO 2 , wherein R C is H or (C 1-4 )alkyl, wherein any R a ; R b , or R c can be mono- or independently multi-substituted with J or R′, or both;
R 2 is H, (C 1-4 )alkyl, or (C 1-5 )acyl, or R 2 together with D and the nitrogen atom to which they are bonded form a phthalimido group, wherein any alkyl, acyl, or phthalimido group is optionally mono- or independently multi-substituted with J or R′, or both;
J, independently at each occurrence, is selected from the group consisting of halogen, (C 1 -C 6 )alkyl, OR′, CN, CF 3 , OCF 3 , ═O, ═S, C(O), S(O), methylenedioxy, ethylenedioxy, (CH 2 ) 0-p N(R′) 2 , (CH 2 ) 0-p SR′, (CH 2 ) 0-p S(O)R′, (CH 2 ) 0-p S(O) 2 R′, (CH 2 ) 0-p S(O) 2 N(R′) 2 , (CH 2 ) 0-p SO 3 R′, (CH 2 ) 0-p C(O)R′, (CH 2 ) 0-p C(O)C(O)R′, (CH 2 ) 0-p C(O)CH 2 C(O)R′, (CH 2 ) 0-p C(S)R′, (CH 2 ) 0-p C(O)OR′, (CH 2 ) 0-p OC(O)R′, (CH 2 ) 0-p C(O)N(R′) 2 (CH 2 ) 0-p OC(O)N(R′) 2 , (CH 2 ) 0-p C(S)N(R′) 2 , (CH 2 ) 0-p NH—C(O)R′, (CH 2 ) 0-p N(R′)N(R′)C(O)R′, (CH 2 ) 0-p N(R′)N(R′)C(O)OR′, (CH 2 ) 0-p N(R′)N(R′)CON(R′) 2 , (CH 2 ) 0-p N(R′)SO 2 R′, (CH 2 ) 0-p N(R′)SO 2 N(R′) 2 , (CH 2 ) 0-p N(R′)C(O)OR′, (CH 2 ) 0-p N(R′)C(O)R′, (CH 2 ) 0-p N(R′)C(S)R′, (CH 2 ) 0-p N(R′)C(O)N(R′) 2 (CH 2 ) 0-p N(R′)C(S)N(R′) 2 , (CH 2 ) 0-p N(COR′)COR′, (CH 2 ) 0-p N(OR′)R′, (CH 2 ) 0-p C(═NH)N(R′) 2 , (CH 2 ) 0-p C(O)N(OR′)R′, and (CH 2 ) 0-p C(═NOR′)R′;
R′, independently at each occurrence, is selected from the group consisting of hydrogen, (C 1 -C 12 )-alkyl, (C 2 -C 12 )-alkenyl, (C 2 -C 12 )-alkynyl , (C 3 -C 10 )-cycloalkyl, (C 3 -C 10 )-cycloalkenyl, [(C 3 -C 10 )cycloalkyl or (C 3 -C 10 )-cycloalkenyl]-[(C 1 -C 12 )-alkyl or (C 2 -C 12 )-alkenyl or (C 2 -C 12 )-alkynyl], monocyclic or bicyclic 3-10 membered heterocyclyl, monocyclic or bicyclic 3-10 membered heterocyclyl-[(C 1 -C 12 )-alkyl or (C 2 -C 12 )-alkenyl or (C 2 -C 12 )-alkynyl], monocyclic or bicyclic 5-10 membered heteroaryl, and monocyclic or bicyclic 5-10 membered heteroaryl-[(C 1 -C 12 )-alkyl or (C 2 -C 12 )-alkenyl or (C 2 -C 12 )-alkynyl], wherein each R′is substituted with 0-3 substituents selected independently from J R ;
or, when two R′ groups are bound to a nitrogen atom or to two adjacent nitrogen atoms, the two R′ groups together with the nitrogen atom or atoms to which they are bound can form a 3- to 8-membered monocyclic heterocyclic ring, or an 8- to 20-membered, bicyclic or tricyclic, heterocyclic ring system, wherein any ring or ring system can further contain 1-3 additional heteroatoms selected from the group consisting of N, NR′, O, S, S(O) and S(O) 2 , wherein each ring is substituted with 0-3 substituents selected independently from J R ; wherein, in any bicyclic or tricyclic ring system, each ring is linearly fused, bridged, or spirocyclic, wherein each ring is either aromatic or nonaromatic, wherein each ring can be fused to a (C 6 -C 10 )aryl, monocyclic or bicyclic 5-10 membered heteroaryl, (C 3 -C 10 )cycloalkyl or monocyclic or bicyclic 3-10 membered heterocyclyl;
J R , independently at each occurrence, is selected from the group consisting of halogen, OR, CN, CF 3 , OCF 3 , ═O, ═S, C(O), S(O), methylenedioxy, ethylenedioxy, (CH 2 ) 0-p N(R) 2 , (CH 2 ) 0-p SR, (CH 2 ) 0-p S(O)R, (CH 2 ) 0-p ,S(O) 2 R, (CH 2 ) 0-p S(O) 2 N(R) 2 , (CH 2 ) 0-p SO 3 R, (CH 2 ) 0-p C(O)R, (CH 2 ) 0-p C(O)C(O)R, (CH 2 ) 0-p C(O)CH 2 C(O)R, (CH 2 ) 0-p C(S)R, (CH 2 ) 0-p C(O)OR, (CH 2 ) 0-p OC(O)R, (CH 2 ) 0-p C(O)N(R) 2 , (CH 2 ) 0-p OC(O)N(R) 2 , (CH 2 ) 0-p C(S)N(R) 2 , (CH 2 ) 0-p NH-C(O)R, (CH 2 ) 0-p N(R)N(R)C(O)R, (CH 2 ) 0-p N(R)N(R)C(O)OR, (CH 2 ) 0-p N(R)N(R)CON(R) 2 , (CH 2 ) 0-p N(R)SO 2 R, (CH 2 ) 0-p N(R)SO 2 N(R) 2 , (CH 2 ) 0-p N(R)C(O)OR, (CH 2 ) 0-p N(R)C(O)R, (CH 2 ) 0-p N(R)C(S)R, (CH 2 ) 0-p N(R)C(O)N(R) 2 , (CH 2 ) 0-p N(R)C(S)N(R) 2 , (CH 2 ) 0-p N(COR)COR, (CH 2 ) 0-p N(OR)R, (CH 2 ) 0-p C(═NH)N(R) 2 , (CH 2 ) 0-p C(O)N(OR)R, and (CH 2 ) 0-p C(═NOR)R;
R, independently at each occurrence, is selected from the group consisting of hydrogen, (C 1 -C 12 )-alkyl, (C 2 -C 12 )-alkenyl, (C 2 -C 12 )-alkynyl, (C 3 -C 10 )-cycloalkyl, (C 3 -C 10 )-cycloalkenyl, [(C 3 -C 10 )cycloalkyl or (C 3 -C 10 )-cycloalkenyl]-[(C 1 -C 12 )-alkyl or (C 2 -C 12 )-alkenyl or (C 2 -C 12 )-alkynyl], (C 6 -C 10 )-aryl, (C 6 -C 10 )-aryl-[(C 1 -C 12 )-alkyl or (C 2 -C 12 )-alkenyl or (C 2 -C 12 )-alkynyl], monocyclic or bicyclic3-10 membered heterocyclyl, monocyclic or bicyclic 3 -10 membered heterocyclyl-[(C 1 -C 12 )-alkyl or (C 2 -C 12 )-alkenyl or (C 2 -C 12 )-alkynyl], monocyclic or bicyclic 5-10 membered heteroaryl, or mono-or bicyclic 5-10 membered heteroaryl-[(C 1 -C 12 )-alkyl or (C 2 -C 12 )-alkenyl or (C 2 -C 12 )-alkynyl]; and
m is 0, 1, 2, 3, 4, or 5;
n is 1, 2, or 3;
p=0, 1, or 2;
r=0, 1, 2, or 3;
or any salt or hydrate thereof.
2. The compound of claim 1 , wherein A is aryl, and wherein A is unsubstituted or is mono- or independently multi-substituted with J or R′, or both.
3. The compound of claim 1 , wherein A is selected from the group consisting of pyrazidinyl, pyrimidinyl, pyrazinyl, thiazolyl, pyrazolyl, pyridyl, and quinolyl, and wherein A is unsubstituted or is mono- or independently multi-substituted with J or R′, or both.
4. The compound of claim 1 , wherein A is unsubstituted.
5. The compound of claim 1 , wherein A is mono-substituted with J or R′.
6. The compound of claim 1 , wherein B is selected from the group consisting of phenyl, pyridyl, pyrazidinyl, pyrimidinyl, pyrazinyl, pyrolyl, pyrazolyl, oxazolyl, imidazolyl, oxadiazolyl, and (1,2,3)-triazolyl, (1,2,4)-triazolyl, and wherein B can be unsubstituted or be mono- or independently multi-substituted with J or R′, or both.
7. The compound of claim 6 , wherein B is selected from the group consisting of pyrolyl, pyrazolyl, oxazolyl, imidazolyl, oxadiazolyl, (1,2,3)-triazolyl, and (1,2,4)-triazolyl.
8. The compound of claim 6 , wherein B is selected from the group consisting of phenyl, pyridyl, pyrimidinyl, and pyrazinyl.
9. The compound of claim 1 , wherein B is unsubstituted.
10. The compound of claim 1 , wherein B is mono-substituted with J or R′.
11. The compound of claim 1 , wherein D is selected from the group consisting of pyridyl, pyridoyl, pyridazinyl, pyridazinoyl, pyrimidinyl, pyrimidinoyl, pyrazinyl, pyrazinoyl, quinolyl, quinoloyl, benzofuranyl, benzofuranoyl, benzoxazolyl, benzoxazoloyl, benzthiazolyl, and benzthiazoloyl; or wherein D combined with R 2 and the nitrogen atom to which they are bonded forms a phthalitnidovl group, and wherein D can be unsubstituted or be mono- or independently multi-substituted with J or R′.
12. The compound of claim 11 , wherein D is selected from the group consisting of pyridoyl, pyridazinoyl, pyrimidinoyl, pyrazinoyl, quinolyl, quinoloyl, benzofuranoyl, benzoxazolyl, benzoxazoloyl, benzthiazolyl, and benzthiazoloyl.
13. The Compound of claim 11 , wherein D is selected from the group consisting of pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinolyl, benzofuranyl, benzoxazolyl, and benthiazolyl.
14. The compound of claim 1 , wherein D is unsubstituted.
15. The compound of claim 1 , wherein D is mono-substituted with J or R′.
16. The compound of claim 1 , wherein J is (C 1 -C 6 )alkyl or halogen.
17. The compound of claim 1 , wherein R′ is hydrogen or (C 1 -C 12 )-alkyl, wherein R′ is substituted with 0-3 substituents selected independently from J R .
18. The compound of claim 1 , wherein J R , independently at each occurrence, is selected from the group consisting of halogen, OR, CN, CF 3 , OCF 3 , and (CH 2 ) 0-p N(R) 2 .
19. The compound of claim 1 , wherein n is 1 or 2.
20. The compound of claim 1 , wherein Z is N.
21. The compound of claim 1 , wherein R 2 is H, (C 1-4 )alkyl, or (C 1-5 )acyl.
22. The compound of claim 1 , wherein R 1 , independently at each occurrence, is selected from the group consisting of halo, oxo, hydroxy, cyano, cycloalkyl, (C 1-4 )alkoxy, aryl, heteroaryl, and (C 1-4 )alkyl.
23. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.